Highlights of the 2012 American Association for the Study of Liver Diseases meeting.
The American Association for the Study of Liver Diseases (AASLD) held its annual meeting from November 9, 2012, through November 13, 2012, in Boston, Massachusetts. Hepatitis C virus (HCV) was prominently featured in the meeting, reflecting the rapid pace at which new developments in the field of HCV treatment are being introduced. HCV was the topic of an estimated 451 of the 2051 submitted abstracts (22%), with 148 abstracts (7.2%) focused on investigational drugs; it was also the topic of 1 presidential plenary session (top oral abstracts), 1 symposium, 10 of 37 parallel sessions (oral abstracts), and 1 debriefing session at the close of the meeting. This article will summarize some of the major findings presented at the meeting.
Case Western Reserve University, Cleveland, OH, USA.
Melissa K
MK
Osborn
D000998:Antiviral Agents / Q000627:therapeutic use*; D001900:Boston; D002986:Clinical Trials as Topic; D060085:Coinfection / Q000188:drug therapy; D004359:Drug Therapy, Combination / Q000379:methods; D015507:Drugs, Investigational / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D006801:Humans; D016896:Treatment Outcome
D000998:Antiviral Agents; D015507:Drugs, Investigational